Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for icosapent

  1. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  2. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

    NICE guideline
    Published
    14 December 2023
    View recommendations

    Sections for NG238

  3. Hundreds of thousands set to benefit as NICE final draft guidance recommends new treatment to prevent heart attacks and strokes in people with raised blood fats

    NICE has today (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.

    News
    Published
    10 June 2022